ApoCell is a leading contract research organization (CRO) specializing in protein biomarker detection and analysis of rare cells in blood and tissue specimens from clinical trial subjects.  We work with industry, government agencies, and academic investigators and can support the biomarker analysis and specimen logistics for all types of projects from preclinical to Phase III trials.

ApoCell has integrated advanced instrumentation platforms to capture quantitative data on each type of specimen available - quantitative biomarker changes on frozen or FFPE tissue or downstream quantitative biomarker analysis of rare cell populations in blood such as circulating tumor cells (CTCs), circulating endothelial cells (CECs) or circulating progenitor cells (CEPs).  To assure optimum sample viability, ApoCell develops and manufactures custom biomarker analysis and site collection kits.  ApoCell can develop and manufacture companion diagnostic testing kits, which helps with patient profiling and truly makes possible the idea of personalized medicine.

We are highly experienced in clinical research support; in the past three years, ApoCell has assisted over 30 clients in biomarker analysis of over 50 trials and studies.

PRECLINICAL AND CLINICAL DEVELOPMENT SERVICES

• TRANSLATIONAL ONCOLOGY
• BIOMARKER DEVELOPMENT
• PHARMACOGENOMICS
• CUSTOM ASSAYS
• TISSUE MICROARRAYS
• CUSTOM ANTIBODIES
• ANTIBODY SCREENING

• SURROGATE MARKERS
• PHARMACODYNAMICS
• COMPOUND OPTIMIZATION
• TARGET VALIDATION
• MECHANISM BIOMARKER
• RARE CELL ANALYSIS
• PROTEIN EXPRESSION

What is your drug's optimal biological dose?

Target Expression Profiling (TEP™) is a proprietary detection and quantification technique that will facilitate identification of pathway changes in response to targeted therapies.

Are you working with an angiogenesis inhibitor?

ApoCell's scientists have developed and mastered techniques that quantify cell signal intensity in the angiogenesis pathway of tumor and endothelial cells from blood, tissue, or fluid specimens. This data is correlative to disease progression and drug intervention outcome.

Are you isolating the correct rare cell phenotype?

ApoCell's integrated rare cell platforms examine more phenotypes and identify the best fit for your needs.

What if you could take your rare cell analysis beyond the count?

ApoCell's proprietary quantitative analysis techniques provide true pharmacodynamic data.

Do you need to enhance the data from your Phase 1 or Phase 2 studies?

ApoCell is a leader in biomarker discovery, assay development, study design and data analysis of primary and surrogate markers of cell signaling, angiogenesis, survival, apoptosis and receptor function.

We conduct prospective and retrospective studies using laser scanning cytometry (LSC) platform and CellSearch™ for signal quantification from tissue or CTC/CEC from whole blood specimens.

We have a highly experienced and skilled scientific and technical team as well as outside expert collaborators from leading institutions and with specialty manufacturers of antibodies and other macromolecules.

Our facilities are GLP and CLIA compliant. Contact us to arrange a teleconference with our scientists.